Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company that develops therapies for life-threatening immune and thrombotic conditions. Its lead drug candidate, CAD-1005, is a selective 12-lipoxygenase inhibitor evaluated for the treatment and prevention of heparin-induced thrombocytopenia. The company's pipeline also includes tecarfarin, an oral vitamin K antagonist intended for patients with end-stage kidney disease and atrial fibrillation or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor for acute hospital care. The company focuses on patient populations with complex anticoagulation requirements and high thrombotic risks.

The company is headquartered in Ponte Vedra, Florida, and is incorporated in Delaware. Operating primarily in the United States biopharmaceutical sector, its research scale includes clinical development programs that span Phase 1 through Phase 3 preparations, with candidate studies evaluating cohorts ranging from small patient groups to more than one thousand clinical subjects.

Summary of the business section of Cadrenal Therapeutics's latest annual report, written by StockData.

“As of March 27, 2025, we had five employees, all of which are full-time, and engage approximately thirty-five consultants and contractors.”